Auranofin

MUSCULO-SKELETAL SYSTEM

Key facts

Auranofin is a drug catalogued in DrugCentral. It was first approved by the FDA in 1985. DrugCentral lists 10 molecular targets, including DRD3, ADRA2A and ADRA2B. Recorded indications include Rheumatoid arthritis.

• Molecular targets: DRD3, ADRA2A, ADRA2B and DRD4 (10 listed in DrugCentral).
• Indications: Rheumatoid arthritis.
• ATC code: M01CB03 (Gold preparations).
• Molecular formula: C20H34AuO9PS; molecular weight 678.48 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Rheumatoid arthritis

Off-label uses (3)

• Felty's syndrome
• Juvenile rheumatoid arthritis
• Psoriasis with arthropathy

Contraindications (22)

• Chronic heart failure
• Colitis
• Diabetes mellitus
• Disease of blood AND/OR blood-forming organ
• Disease of liver
• Eczema
• Eruption of skin
• Erythroderma
• Fibrosis of lung
• Hypertensive disorder
• Inflammatory disease of liver
• Kidney disease
• Leukopenia
• Necrotizing enterocolitis in fetus OR newborn
• Neutropenic disorder
• Pregnancy, function
• Severe Debilitation
• Sjögren's syndrome
• Systemic lupus erythematosus
• Thrombocytopenic disorder
• Ultraviolet light therapy
• Urticaria

Mechanism & targets

Molecular targets (10)

Target	Gene	Action	Activity
D(3) dopamine receptor	DRD3	unknown	Ki 6.65
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.48
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.44
D(4) dopamine receptor	DRD4	unknown	Ki 6.41
Glucocorticoid receptor	NR3C1	unknown	Ki 6.22
Adenosine receptor A3	ADORA3	unknown	Ki 6.02
Transient receptor potential cation channel subfamily A member 1	TRPA1	activator	EC50 6.00
Tyrosine-protein kinase Fyn	FYN	unknown	IC50 5.92
Arachidonate 5-lipoxygenase	ALOX5	unknown	—
Thioredoxin reductase 1, cytoplasmic	TXNRD1	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-05-24	FDA	—	PROMETHEUS LABS

ATC classification

ATC code	Therapeutic hierarchy
M01CB03	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › SPECIFIC ANTIRHEUMATIC AGENTS › Gold preparations

Chemical structure

• Molecular formula: C₂₀H₃₄AuO₉PS
• Molecular weight: 678.48 g/mol
• CAS number: 34031-32-8
• InChIKey: —
• PubChem CID: 16667669

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Auranofin used for?

DrugCentral lists the following indications for Auranofin: Rheumatoid arthritis.

How does Auranofin work?

Its molecular targets in DrugCentral include DRD3, ADRA2A, ADRA2B and DRD4.

When was Auranofin first approved?

Auranofin was first approved by the FDA in 1985.

What is the chemical formula of Auranofin?

Auranofin has the molecular formula C20H34AuO9PS and a molecular weight of 678.48 g/mol.

Sources

• DrugCentral drug card 4122 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1366 — compound record and bioactivity
• PubChem CID 16667669 — chemical identifiers
• DrugBank DB00995 — drug record
• FDA UNII 3H04W2810V — substance identity
• DailyMed: FDA labels for Auranofin — current prescribing information (label search)
• UniProt P35462 (DRD3) — target protein
• UniProt P08913 (ADRA2A) — target protein
• UniProt P18089 (ADRA2B) — target protein
• UniProt P21917 (DRD4) — target protein
• UniProt P04150 (NR3C1) — target protein
• UniProt P0DMS8 (ADORA3) — target protein

How this page is built: methodology · editorial policy & corrections.